Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Gross Margin (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Gross Margin for 16 consecutive years, with 62.65% as the latest value for Q4 2025.

  • Quarterly Gross Margin rose 668.0% to 62.65% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 56.56% through Dec 2025, down 682.0% year-over-year, with the annual reading at 56.56% for FY2025, 682.0% down from the prior year.
  • Gross Margin for Q4 2025 was 62.65% at Anika Therapeutics, up from 56.02% in the prior quarter.
  • The five-year high for Gross Margin was 66.69% in Q2 2024, with the low at 199.14% in Q4 2023.
  • Average Gross Margin over 5 years is 36.69%, with a median of 58.83% recorded in 2022.
  • The sharpest move saw Gross Margin tumbled -18607bps in 2022, then soared 25510bps in 2024.
  • Over 5 years, Gross Margin stood at 50.62% in 2021, then plummeted by -368bps to 135.45% in 2022, then crashed by -47bps to 199.14% in 2023, then soared by 128bps to 55.96% in 2024, then increased by 12bps to 62.65% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 62.65%, 56.02%, and 50.9% for Q4 2025, Q3 2025, and Q2 2025 respectively.